Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzheng Huayu Combined With Entecavir in Low-grade Cirrhotic Portal Hypertension Due to HBV
NCT02945956Phase 4Unknown
- Sponsor
- Shuguang Hospital
- Start
- Apr 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fuzheng huayu in Portal Hypertension (PH) and Liver cirrhosis (LC) (2 arms), sponsored by Shuguang Hospital. Primary endpoints: Incidence of clinical events: Variceal hemorrhage, Ascites, Encephalopathy, etc at 96 weeks, Grading varices at 96 weeks and 2 more. Status: unknown.
02
Drugs
fuzheng huayu
03
Conditions
Portal Hypertension (PH)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT02945956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945956.